Ascentage Pharma Group Inc.

This study tests an experimental pill called HQP1351 in people with chronic myeloid leukemia (CML) or a type of acute lymphoblastic leukemia (Ph+ ALL) that has not responded to at least two prior treatments. The goal is to find the best dose and see how safe and effective the dru…

This study tests whether adding the experimental drug APG-2575 (Lisaftoclax) to the standard medicine azacitidine helps older adults with newly diagnosed acute myeloid leukemia (AML) live longer. About 486 participants who cannot have strong chemotherapy will receive either the c…

This study tests whether adding a new drug, lisaftoclax, to standard BTK inhibitor therapy can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma live longer without their cancer getting worse. About 400 adults who have already been treated with a BTK inh…

This study tests a new drug called APG-2575 in people whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to other treatments. About 75 adults will take the drug alone to see if it shrinks tumors and how safe it is. The goal is to …

This phase 3 trial tests whether a new targeted drug (olverembatinib) combined with chemotherapy works better than other standard targeted drugs plus chemotherapy for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). About 350 pa…

This study is testing a new drug called APG-2575 in 40 people with mild-to-moderate lupus. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure …

This early-phase study tests an oral drug called HQP1351 in about 100 people with advanced GIST (a type of stomach tumor) or other solid tumors. The main goal is to find a safe dose and see how the body processes the drug. Researchers will also watch for any signs that the drug s…

This study tests two experimental drugs, APG-115 and APG-2575, in people with T-cell prolymphocytic leukemia (T-PLL) or non-Hodgkin's lymphoma (NHL) that has come back or stopped responding to treatment. The main goal is to find the safest dose and see how well the drugs work. Ab…

This study tests whether adding the experimental drug lisaftoclax to standard chemotherapy (azacitidine) helps people with a newly diagnosed, aggressive form of myelodysplastic syndrome (HR-MDS) live longer. About 490 adults worldwide will be randomly assigned to receive either t…

This study tests a new drug called lisaftoclax (APG-2575) in people with acute myeloid leukemia (AML) that has returned or not improved with standard treatments. The drug is given alone or together with other medicines (homoharringtonine or azacitidine). The main goals are to che…

This early-stage study tests a new drug called APG-5918 in 105 healthy volunteers and people with anemia (low red blood cells). The main goal is to check safety and how the drug moves through the body. Researchers will also see if it helps raise hemoglobin levels to ease anemia s…

This study looks at how the body processes a single dose of the drug olverembatinib in people with different levels of liver function. About 48 adults with either normal or impaired liver function will take part. The goal is to measure drug levels and safety, not to treat any dis…